Intercept Blood System

Cerus Corporation is a biomedical products company focused on the field of blood transfusion safety. The company's core technology is the INTERCEPT Blood System, which utilizes a proprietary pathogen inactivation process to enhance the safety of blood components. By targeting and cross-linking nucleic acids, the system inactivates a broad spectrum of viruses, bacteria, and parasites in platelets, plasma, and red blood cells. Cerus is dedicated to establishing its technology as the global standard for blood centers and hospitals to prevent transfusion-transmitted infections. The company also markets the INTERCEPT Fibrinogen Complex for the treatment of bleeding associated with fibrinogen deficiency. Cerus maintains strategic partnerships with major blood centers and regulatory bodies to expand the adoption of its safety technologies worldwide.